Perspective Therapeutics Q2 net loss widens on higher R&D costs
CATX•Analyst views and peer context
The current average analyst rating on the shares is "buy", with 13 analysts rating the stock "strong buy" or "buy", 1 rating it "hold", and none rating it "sell" or "strong sell".
The average consensus recommendation for the biotechnology and medical research peer group is "buy".
Wall Street's median 12-month price target for Perspective Therapeutics Inc is $13.00, about 333.3% above its August 7 closing price of $3.00.
Q2 loss widens as R&D spending rises
Perspective Therapeutics said its second-quarter net loss widened as research and development expenses increased, reflecting spending as multiple clinical programs advanced.
The US radiopharmaceutical developer reported a second-quarter loss per share of $0.22 and a net loss of $26.79 million. Net income from continuing operations was -$26.98 million, while operating income was .
